Selected research
Market Structure
Global Antibody Fragments Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Antibody Fragments market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Antibody Fragments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Antibody Fragments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Antibody Fragments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Antibody Fragments is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Antibody Fragments include AbbVie, Amgen, Biogen, Bristol-Myers Squibb, F. Hoffmann-La Roche, Eli Lilly, Novartis, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Antibody Fragments market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Antibody Fragments and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Antibody Fragments sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antibody Fragments market size, projected growth trends, production technologies, key applications, and end-use industries.
Antibody Fragments Segment by Company
AbbVie
Amgen
Biogen
Bristol-Myers Squibb
F. Hoffmann-La Roche
Eli Lilly
Novartis
Johnson & Johnson
Sanofi
Takeda Pharmaceutical
Antibody Fragments Segment by Type
F(ab) Fragment
F(ab’)2 Fragment
Antibody Fragments Segment by Application
Cancer
Immunodeficiencies
Other
Antibody Fragments Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Fragments market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Fragments and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Fragments.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Antibody Fragments market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Fragments manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antibody Fragments in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Antibody Fragments in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- F(ab) Fragment
- F(ab’)2 Fragment
Applications
- Cancer
- Immunodeficiencies
- Other
Companies covered
- AbbVie
- Amgen
- Biogen
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Eli Lilly
- Novartis
- Johnson & Johnson
- Sanofi
- Takeda Pharmaceutical
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Antibody Fragments Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Antibody Fragments Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Antibody Fragments Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Antibody Fragments Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Antibody Fragments Market Dynamics
- 2.1 Antibody Fragments Industry Trends
- 2.2 Antibody Fragments Industry Drivers
- 2.3 Antibody Fragments Industry Opportunities and Challenges
- 2.4 Antibody Fragments Industry Restraints
3 Antibody Fragments Market by Manufacturers
- 3.1 Global Antibody Fragments Revenue by Manufacturers (2021-2026)
- 3.2 Global Antibody Fragments Sales by Manufacturers (2021-2026)
- 3.3 Global Antibody Fragments Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Antibody Fragments Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Antibody Fragments Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Antibody Fragments Manufacturers, Product Type & Application
- 3.7 Global Antibody Fragments Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Antibody Fragments Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Antibody Fragments Players Market Share by Revenue in 2025
- 3.8.3 2025 Antibody Fragments Tier 1, Tier 2, and Tier 3
4 Antibody Fragments Market by Type
- 4.1 Antibody Fragments Type Introduction
- 4.1.1 F(ab) Fragment
- 4.1.2 F(ab’)2 Fragment
- 4.2 Global Antibody Fragments Sales by Type
- 4.2.1 Global Antibody Fragments Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Antibody Fragments Sales by Type (2021-2032)
- 4.2.3 Global Antibody Fragments Sales Market Share by Type (2021-2032)
- 4.3 Global Antibody Fragments Revenue by Type
- 4.3.1 Global Antibody Fragments Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Antibody Fragments Revenue by Type (2021-2032)
- 4.3.3 Global Antibody Fragments Revenue Market Share by Type (2021-2032)
5 Antibody Fragments Market by Application
- 5.1 Antibody Fragments Application Introduction
- 5.1.1 Cancer
- 5.1.2 Immunodeficiencies
- 5.1.3 Other
- 5.2 Global Antibody Fragments Sales by Application
- 5.2.1 Global Antibody Fragments Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Antibody Fragments Sales by Application (2021-2032)
- 5.2.3 Global Antibody Fragments Sales Market Share by Application (2021-2032)
- 5.3 Global Antibody Fragments Revenue by Application
- 5.3.1 Global Antibody Fragments Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Antibody Fragments Revenue by Application (2021-2032)
- 5.3.3 Global Antibody Fragments Revenue Market Share by Application (2021-2032)
6 Global Antibody Fragments Sales by Region
- 6.1 Global Antibody Fragments Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Antibody Fragments Sales by Region (2021-2032)
- 6.2.1 Global Antibody Fragments Sales by Region (2021-2026)
- 6.2.2 Global Antibody Fragments Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Antibody Fragments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Antibody Fragments Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Antibody Fragments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Antibody Fragments Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Antibody Fragments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Antibody Fragments Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Antibody Fragments Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Antibody Fragments Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Antibody Fragments Revenue by Region
- 7.1 Global Antibody Fragments Revenue by Region
- 7.1.1 Global Antibody Fragments Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Antibody Fragments Revenue by Region (2021-2026)
- 7.1.3 Global Antibody Fragments Revenue by Region (2027-2032)
- 7.1.4 Global Antibody Fragments Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Antibody Fragments Revenue (2021-2032)
- 7.2.2 North America Antibody Fragments Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Antibody Fragments Revenue (2021-2032)
- 7.3.2 Europe Antibody Fragments Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Antibody Fragments Revenue (2021-2032)
- 7.4.2 Asia-Pacific Antibody Fragments Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Antibody Fragments Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Antibody Fragments Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 AbbVie
- 8.1.1 AbbVie Company Information
- 8.1.2 AbbVie Business Overview
- 8.1.3 AbbVie Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 AbbVie Antibody Fragments Product Portfolio
- 8.1.5 AbbVie Recent Developments
- 8.2 Amgen
- 8.2.1 Amgen Company Information
- 8.2.2 Amgen Business Overview
- 8.2.3 Amgen Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Amgen Antibody Fragments Product Portfolio
- 8.2.5 Amgen Recent Developments
- 8.3 Biogen
- 8.3.1 Biogen Company Information
- 8.3.2 Biogen Business Overview
- 8.3.3 Biogen Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Biogen Antibody Fragments Product Portfolio
- 8.3.5 Biogen Recent Developments
- 8.4 Bristol-Myers Squibb
- 8.4.1 Bristol-Myers Squibb Company Information
- 8.4.2 Bristol-Myers Squibb Business Overview
- 8.4.3 Bristol-Myers Squibb Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Bristol-Myers Squibb Antibody Fragments Product Portfolio
- 8.4.5 Bristol-Myers Squibb Recent Developments
- 8.5 F. Hoffmann-La Roche
- 8.5.1 F. Hoffmann-La Roche Company Information
- 8.5.2 F. Hoffmann-La Roche Business Overview
- 8.5.3 F. Hoffmann-La Roche Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 F. Hoffmann-La Roche Antibody Fragments Product Portfolio
- 8.5.5 F. Hoffmann-La Roche Recent Developments
- 8.6 Eli Lilly
- 8.6.1 Eli Lilly Company Information
- 8.6.2 Eli Lilly Business Overview
- 8.6.3 Eli Lilly Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Eli Lilly Antibody Fragments Product Portfolio
- 8.6.5 Eli Lilly Recent Developments
- 8.7 Novartis
- 8.7.1 Novartis Company Information
- 8.7.2 Novartis Business Overview
- 8.7.3 Novartis Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Novartis Antibody Fragments Product Portfolio
- 8.7.5 Novartis Recent Developments
- 8.8 Johnson & Johnson
- 8.8.1 Johnson & Johnson Company Information
- 8.8.2 Johnson & Johnson Business Overview
- 8.8.3 Johnson & Johnson Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Johnson & Johnson Antibody Fragments Product Portfolio
- 8.8.5 Johnson & Johnson Recent Developments
- 8.9 Sanofi
- 8.9.1 Sanofi Company Information
- 8.9.2 Sanofi Business Overview
- 8.9.3 Sanofi Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Sanofi Antibody Fragments Product Portfolio
- 8.9.5 Sanofi Recent Developments
- 8.10 Takeda Pharmaceutical
- 8.10.1 Takeda Pharmaceutical Company Information
- 8.10.2 Takeda Pharmaceutical Business Overview
- 8.10.3 Takeda Pharmaceutical Antibody Fragments Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Takeda Pharmaceutical Antibody Fragments Product Portfolio
- 8.10.5 Takeda Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Antibody Fragments Value Chain Analysis
- 9.1.1 Antibody Fragments Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Antibody Fragments Production Mode & Process
- 9.2 Antibody Fragments Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Antibody Fragments Distributors
- 9.2.3 Antibody Fragments Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst